In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Neurogene, with a price target of $65.00.TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Dolezal covers the Healthcare sector, focusing on stocks such as Neurogene, Oculis Holding, and Ibio. According to TipRanks, Dolezal has an average return of 16.3% and a 44.34% success rate on recommended stocks.
In a report released on July 6, Stifel Nicolaus also maintained a Buy rating on the stock with a $46.00 price target.
Based on Neurogene’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $30.93 million. In comparison, last year the company had a GAAP net loss of $22.65 million
